We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+18.58%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$115M
AUM Growth
+$7.3M
Cap. Flow
-$5.59M
Cap. Flow %
-4.84%
Top 10 Hldgs %
66.83%
Holding
65
New
5
Increased
9
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.5M
2
EQT icon
EQT Corp
EQT
+$1.18M
3
ATEC icon
Alphatec Holdings
ATEC
+$844K
4
CSTL icon
Castle Biosciences
CSTL
+$611K
5
KALV
KalVista Pharmaceuticals
KALV
+$453K

Top Sells

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$4.27M
2
HROW icon
Harrow
HROW
+$2.61M
3
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$1.73M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$1.65M
5
OVV icon
Ovintiv
OVV
+$951K

Sector Composition

Rank Sector Weight
1 Healthcare 97.17%
2 Energy 2.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
26
10x Genomics
TXG
$5.49B
$677K 0.59%
30,000
– –
HALO icon
27
Halozyme
HALO
$9.14B
$572K 0.5%
10,000
– –
AXDX
28
DELISTED
Accelerate Diagnostics
AXDX
$556K 0.48%
325,239
– –
CYTK icon
29
Cytokinetics
CYTK
$10.7B
$528K 0.46%
10,000
– –
INBX icon
30
Inhibrx
INBX
$1.23B
$503K 0.44%
32,110
+20,000
+165% +$281K
KROS icon
31
Keros Therapeutics
KROS
$210M
$406K 0.35%
7,000
– –
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
$404K 0.35%
14,000
– –
TMCI icon
33
Treace Medical Concepts
TMCI
$274M
$396K 0.34%
+68,350
New +$439K
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.38B
$394K 0.34%
10,000
– –
KPTI icon
35
Karyopharm Therapeutics
KPTI
$169M
$390K 0.34%
31,322
– –
CHRS icon
36
Coherus Oncology
CHRS
$219M
$387K 0.34%
372,000
+102,000
+38% +$140K
ARVN icon
37
Arvinas
ARVN
$517M
$369K 0.32%
15,000
– –
PGNY icon
38
Progyny
PGNY
$2.49B
$369K 0.32%
22,000
– –
BHVN
39
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$368K 0.32%
7,365
– –
AXSM icon
40
Axsome Therapeutics
AXSM
$11.4B
$359K 0.31%
4,000
– –
CGEM icon
41
Cullinan Oncology
CGEM
$1.08B
$335K 0.29%
20,000
– –
WVE icon
42
Wave Life Sciences
WVE
$1.1B
$328K 0.28%
40,000
– –
SWTX
43
DELISTED
SpringWorks Therapeutics
SWTX
$320K 0.28%
10,000
– –
NVCR icon
44
NovoCure
NVCR
$1.85B
$313K 0.27%
20,000
– –
SRPT icon
45
Sarepta Therapeutics
SRPT
$1.78B
$312K 0.27%
2,500
– –
BCRX icon
46
BioCryst Pharmaceuticals
BCRX
$2.32B
$304K 0.26%
40,000
– –
FOLD
47
DELISTED
Amicus Therapeutics
FOLD
$299K 0.26%
28,000
– –
BPMC
48
DELISTED
Blueprint Medicines
BPMC
$250K 0.22%
+2,700
New +$268K
XNCR icon
49
Xencor
XNCR
$1.39B
$247K 0.21%
12,300
– –
GOSS icon
50
Gossamer Bio
GOSS
$68.9M
$136K 0.12%
138,176
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Birchview Capital held 65 positions worth $115M, up 6.7% from $108M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Birchview Capital withdrew a net $5.59M in Q3 2024, closing 4 positions and reducing 7 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $4.27M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Energy.

Against the trend, Birchview Capital opened a new position in EQT Corp worth $1.27M.

  • Birchview Capital's largest Q3 2024 buy was EQT Corp: 34,619 shares worth $1.27M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q3 2024, an estimated $2.5M increase.
  • Birchview Capital's biggest Q3 2024 reduction was Harrow, cutting an estimated $2.61M.
  • Birchview Capital fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $4.27M.
  • Birchview Capital's ten largest holdings make up 67% of its $115M portfolio in Q3 2024.
  • Birchview Capital opened 5 new positions and closed 4 in Q3 2024.
  • Birchview Capital's portfolio value rose 6.7% quarter-over-quarter to $115M.

Based on Birchview Capital's 13F filing for Q3 2024, filed 14 Nov 2024.